Related Experiment Video
Updated: Mar 3, 2026
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Preclinical models for translational sarcoma research
Rainer Hamacher1, Sebastian Bauer
1aDepartment of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen bGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Purpose Of Review:
Sarcoma is a basket term for mesenchymal tumors for which more than 75 genetically and histologically distinct subtypes are recognized. Therapeutic progress has largely been achieved with classical chemotherapeutic drugs that were tested in empirical clinical trials. However, outcome in metastatic patients remains poor and with few exceptions numerous trials have failed or only provided limited improvement in recent years.
Recent Findings:
Given the genomic heterogeneity, preclinical model systems will be indispensable to identify new molecular targets and to prioritize drugs and drug combinations. Cell culture is still widely used in preclinical sarcoma research to identify potential novel therapeutic approaches and resistance mechanisms. New and improved techniques in genome-wide and proteome-wide screens enable a better characterization. In addition to cell line xenograft mouse models, patient-derived xenografts crucially broadened and improved preclinical studies using primary human samples. Finally, novel strategies for genome editing, like CRISPR/Cas and sleeping beauty transposon, lead to development of novel genetically engineered cell lines and mouse models.
Summary:
The present review gives a non-comprehensive overview on current model systems used in sarcoma research and discusses their translational relevance. Those include cell lines, subtype-specific patient-derived cell lines and xenografts as well as developments in genome editing and genetically engineered cell lines and mouse models.
Insights
Advancements in sarcoma research rely on sophisticated preclinical models. These models, including cell lines and patient-derived xenografts, are crucial for identifying new therapeutic targets and improving patient outcomes in sarcoma treatment.
Area of Science:
- Oncology
- Translational Research
- Genomics
Background:
- Sarcoma encompasses over 75 subtypes of mesenchymal tumors.
- Current chemotherapies offer limited improvement for metastatic sarcoma patients.
- Genomic heterogeneity poses challenges for effective sarcoma treatment.
Purpose of the Study:
- To review current preclinical model systems in sarcoma research.
- To discuss the translational relevance of these models.
- To highlight advancements in developing novel sarcoma models.
Main Methods:
- Utilizing cell culture for identifying therapeutic approaches and resistance mechanisms.
- Employing genome-wide and proteome-wide screening techniques.
- Developing patient-derived xenografts and genetically engineered models.
Main Results:
- Preclinical models are essential for identifying molecular targets and prioritizing drug combinations.
- Patient-derived xenografts improve preclinical studies with primary human samples.
- Genome editing technologies facilitate the creation of novel cell lines and mouse models.
Conclusions:
- Current sarcoma research employs diverse model systems, including cell lines and xenografts.
- Advancements in genome editing are leading to improved genetically engineered models.
- These models are vital for advancing sarcoma therapeutics and understanding resistance mechanisms.
